SIU School of Medicine

Jump directly to a section:

LONGITUDINAL BEHAVIORAL OUTCOMES IN SURGICAL AND MEDICAL LUNG CANCER PATIENTS

IRB Number

04-105

Trial Status

Open for Enrollment
Phase 3

Why is this study being done?

The purpose of this study is to examine the degree of emotional distress, hopefulness, and positive outlook of participants with lung cancer.

Who is eligible to participate?

Lung cancer patients <8 weeks after diagnosis, initiation of chemotherapy and/or radiation, or surgery. The study is for patients with non-small cell lung cancer or with small cell lung cancer.

What is involved?

We will examine the outcomes of surgically and medically treated lung cancer patients who consent to participate. Tools will be administered postoperatively within 8 weeks of patient diagnosis or surgery for baseline assessment and at 2 weeks, 6 weeks, 3 months, 6 months and annually. The timeline of surgery will be used for all surgical patients. Patients treated medically will be enrolled within 8 weeks of diagnosis or initiation of therapy (radiation or chemotherapy). The tools may be mailed to the patient if the patient is not being seen for a clinical reason. The goal is to enroll up to 500 subjects in the study. Four to six new lung cancer patients are in the surgical or medical clinics per week. Based on our previous enrollment we anticipate enrolling 10 patients per month.

How long is the study?

Tools will be administered postoperatively within 8 weeks of patient diagnosis or surgery for baseline assessment and at 2 weeks, 6 weeks, 3 months, 6 months and annually. The timeline of surgery will be used for all surgical patients. Patients treated medically will be enrolled within 8 weeks of diagnosis or initiation of therapy (radiation or chemotherapy). The tools may be mailed to the patient if the patient is not being seen for a clinical reason. The goal is to enroll up to 500 subjects in the study. Four to six new lung cancer patients are in the surgical or medical clinics per week. Based on our previous enrollment we anticipate enrolling 10 patients per month.

Who can I contact for additional information?

Please contact Theresa Boley, RN, MSN, APN/FNP, CCRP at 217-545-5000 or email tboley@siumed.edu

Who is the Principal Investigator of this study?

Theresa Boley, APN

Where is the trial located?

Springfield, Illinois